← Leaderboards
Yibin Yang
Research Inst Of Fox Chase Can Ctr
$4,715,172
Attributed
$4,715,172
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $845.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,715,172 · 3
By mechanism
R01$4,131,324 · 2
K22$583,848 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsCell SurvivalPathogenesisSignal TransductionProteinsXenograft ModelTumorMalignant Lymphoid NeoplasmLibrariesInsightPhenotypeIn VitroPublic HealthLoss Of FunctionGrowthNovel StrategiesPathologicCytokineInflammatoryGenesMolecularNovel Therapeutic InterventionCrispr LibraryCrispr Screen
Grant awards (13)
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma$427,763
R01 · FY2025 · CA · contact PI
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy$410,489
R01 · FY2025 · CA · contact PI
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma$406,375
R01 · FY2024 · CA · contact PI
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy$383,481
R01 · FY2024 · CA · contact PI
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma$419,207
R01 · FY2023 · CA · contact PI
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy$395,588
R01 · FY2023 · CA · contact PI
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma$427,763
R01 · FY2022 · CA · contact PI
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy$415,375
R01 · FY2022 · CA · contact PI
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma$427,763
R01 · FY2021 · CA · contact PI
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy$417,520
R01 · FY2021 · CA · contact PI
Analysis and Therapeutic Targeting Non-proteolytic Protein Ubiquitination in Diffuse Large B Cell Lymphoma$194,616
K22 · FY2018 · CA · contact PI
Analysis and Therapeutic Targeting Non-proteolytic Protein Ubiquitination in Diffuse Large B Cell Lymphoma$194,616
K22 · FY2017 · CA · contact PI
Analysis and Therapeutic Targeting Non-proteolytic Protein Ubiquitination in Diffuse Large B Cell Lymphoma$194,616
K22 · FY2016 · CA · contact PI